Aclysiran, an RNAi therapeutic agent targeting ACLY, treats hypercholesterolemia and atherosclerosis in ApoE–/– mice
Saved in:
| Main Authors: | Meijie Chen, Peter J. Little, Sudong Kong, Maciej Banach, Jianping Weng, Suowen Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383524004088 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modern ultrasound methods and atherosclerosis assessment in patients with familial hypercholesterolemia
by: A. I. Ershova, et al.
Published: (2011-06-01) -
A Review on Single-Phase AC-AC Z-Source Converters
by: Ebrahim Babaei, et al.
Published: (2022-06-01) -
Tailored polysaccharide entrapping metal-organic framework for RNAi therapeutics and diagnostics in atherosclerosis
by: Sen Li, et al.
Published: (2025-01-01) -
Genetic variants and carotid atherosclerosis progression in familial hypercholesterolemia: a comprehensive review
by: Makhabbat Bekbossynova, et al.
Published: (2025-05-01) -
2024 Polish recommendations for the management of familial hypercholesterolemia in children and adolescents
by: Małgorzata Myśliwiec, et al.
Published: (2024-11-01)